These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2009-018240-23 A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma 2013-05-21 bad-data
Exempt 2011-004250-26 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor 2019-03-27 not-yet-due
Exempt 2011-005215-86 A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC) 2018-08-16 not-yet-due
Ongoing 2013-000517-20 A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer not-yet-due
Ongoing 2013-000518-39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serou... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2013-003874-29 A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related ge... 2016-07-28 bad-data
Ongoing 2013-005532-23 TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) not-yet-due
Not reported 2014-000370-19 TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) 2017-07-03 due-trials
Not reported 2014-003437-26 TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Canc... 2018-03-29 due-trials
Ongoing 2016-000816-14 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, ... not-yet-due
Ongoing 2016-003162-13 TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency not-yet-due
Ongoing 2016-003163-20 TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homolog... not-yet-due
Listed as ongoing, but also has a completion date 2017-004166-10 A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma 2019-04-07 bad-data
Ongoing 2017-004557-17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platin... not-yet-due